Patients and Survivors

自上次CCSG审查以来，患者和幸存者计划的范围已从12个成员扩大到19个成员 反映出癌症中心和研究所支持的新的招聘机会。同行评议总数 该计划领域的资金为1100万美元，其中300万美元(27%)来自国家癌症 研究所(该计划领域的资金总额自2002年以来增加了200万美元)。我们目前与癌症相关的 发表论文284篇(平均15篇/成员)，其中30%是在《美国医学会杂志》等高影响力期刊上发表的， 《临床肿瘤学与临床癌症研究杂志》。方案内出版物有 从上次审查时的15%增加到目前的40%，方案间出版物保持不变 大致相同(现在为8%，上次评估为10%)。正如后面所讨论的，我们现在有了几个新的 资助的赠款是在此期间方案间和翻译研究合作的结果 在过去的供资期间，我们预计这将导致方案间出版物的增加。 下一个赠款周期。PS计划区域组合中只有几个治疗性试验；然而，我们 是否有许多患者同时被招募到干预和观察性非治疗性临床 研究研究，来自不同种族的人群。

Since the past CCSG review, the Patients and Survivors Program Area has expanded from 12 to 19 members reflecting new recruitment opportunities supported by the Cancer Center and the Institution. Total peerreviewed funding for the program area is $11 million, including $3 million (27%) from the National Cancer Institute (overall funding for this Program Area has increased by $2 million since 2002). Our current cancerrelevant publications number 284 (average 15/member), with 30% in high impact journals such as JAMA, JNCI, the Journal of Clinical Oncology, and Clinical Cancer Research. Intra-programmatic publications have increased from 15% at last review to 40% currently, while inter-programmatic publications have remained about the same (8% now vs. 10% at last review). As is discussed later, we now have in place several new funded grants that are the result of inter-programmatic and translational research collaborations during this past funding period, and we expect that these will lead to an increase in inter-programmatic publications in the next grant cycle. Only a few therapeutic trials are represented in the PS Program Area portfolio; however, we have many patients who have been recruited to both intervention and observational non-therapeutic clinical research studies, from ethnically diverse populations.